Much of the pharmacologic treatment options for NF1 pain remain in clinical and preclinical stages, including those that target mTOR or MEK pathways for malignant peripheral nerve sheath tumors [3]. This evidence concerns the gene MAP2K7 and malignant peripheral nerve sheath tumor.